Anika reports inducement grants under nasdaq listing rule 5635(c)(4)

Bedford, mass., april 07, 2025 (globe newswire) -- anika therapeutics, inc. (nasdaq: anik), a global leader in the osteoarthritis (“oa”) pain management and regenerative solutions space focused on early intervention orthopedics, today announced that on april 1, 2025, anika granted non-statutory stock options (“options”) covering an aggregate of 3,800 shares of common stock at a per share exercise price of $15.03, which equaled the closing price of common stock on the nasdaq global select market (“closing price”) on the grant date, to one newly hired non-executive employee. the grant was made pursuant to the anika therapeutics, inc. 2021 inducement plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with nasdaq listing rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with anika as a component of the grantee's employment compensation.
ANIK Ratings Summary
ANIK Quant Ranking